Top 30 shareholders holding app 71% shareholding in HT and with the balance float is approximately 29 mil shares floating is considered small float. With EPS of 10.83 sen and PE ratio of 13 which is low consider the industry the company i is technology.
Good potential for the company to grow further as major clients are reputable parties Regal Orion Sdn Bhd which considered big player in big data and will allowed company to generate good stream of income from the agreement enter into
With Wong TS who recently emerges as shareholder of widetech approximately 12.3% and his holding in HT Padu which he will not be acting passively in his investment, hence can see HT Padu have a good prospect with S5 also in the cards for the group to reliase
TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) : NON RELATED PARTY TRANSACTIONS MY E.G. Services Berhad ("MYEG" or "the Company") - Joint Venture Agreements entered between:- (1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and (2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company.
MY E.G. SERVICES BERHAD
Type Announcement Subject TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS Description MY E.G. Services Berhad ("MYEG" or "the Company") - Joint Venture Agreements entered between:-
(1) Shigatse Service Co., Ltd. and MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company; and (2) SinoPhil Biotech Inc., Shigatse Service Co., Ltd. and I-PAY MYEG Philippines Inc., a joint venture company of the Company. The Board of Directors of the Company wishes to announce that MYEG Medical Services Sdn. Bhd., a wholly-owned sub-subsidiary of the Company and I-Pay MYEG Philippines Inc., a joint venture company of the Company, had on 17 June 2021 entered into joint venture agreements respectively in their respective territories.
Please refer to the attachment for further details.
KUALA LUMPUR (Bernama) -- My E.G. Services Bhd has signed a letter of intent (LOI) to purchase 10 million doses of Anhui Zhifei Biopharmaceutical Co Ltd’s COVID-19 vaccine, ensuring that the corresponding quantity of its recombinant protein subunit vaccine is reserved for delivery as early as August.
In a filing with Bursa Malaysia, MYEG said it holds three-year rights to exclusively distribute the vaccine in Malaysia while through a separate partnership, the group has two-year exclusive distribution rights to the vaccine in the Philippines and is presently in discussions to distribute in other countries.
"Last week, MYEG announced plans for the roll-out of a vaccination programme in the Philippines that will cover the provision of the vaccines to the public health segment as well as private sales,” it said.
The LOI is to ensure that the corresponding quantity of Zhifei’s recombinant protein subunit vaccine is reserved for delivery as early as August when vaccination through the private market is enabled.
"This paves the way for the vaccine to be imported and made available to Malaysians as soon as the private market commences and subject to the conditional authorisation of the vaccine by the National Pharmaceutical Regulatory Agency (NPRA),” it said.
The cost of the vaccine will be determined later subject to the conditional authorisation by NPRA.
MYEG said it is confident that when the Zhifei vaccine becomes available locally, it can play an important role in accelerating the country’s drive towards achieving herd immunity against the COVID-19 virus.
Jointly developed by Zhifei and the Institute of Microbiology of the Chinese Academy of Sciences, the vaccine has fast emerged as among the preferred vaccines in China since gaining emergency use authorisation there in early March in view of its distinct inherent advantages as a recombinant protein subunit vaccine. More than 60 million doses have already been administered in more than a dozen provincial-level regions, including Beijing. The vaccine is also being used in Uzbekistan.
Recombinant protein technology is proven, having been used for the development of vaccines such as hepatitis B and shingles.
In addition, recombinant protein vaccines can be more easily produced at a large-scale since production does not need to be carried out in high-grade biosafety laboratories, and they are also more cost-effective and easier to store and transport.
Since the outbreak of the COVID-19 virus, MYEG has leveraged its strengths and expertise as a leading digital services provider in the region to introduce a number of significant initiatives as part of a holistic solution aimed at helping in the fight against the pandemic.
Besides vaccines, these offerings include screening services, quarantine management and digital health travel pass systems.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....